Triazole‐ and Imidazole‐Containing Compounds: Versatile VEGFR‐2 Inhibitors for Cancer Therapy
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70330 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Parisa Nikfar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Triazoles, Vascular Endothelial Growth Factor Receptor-2, Imidazoles, Antineoplastic Agents. Die Arbeit nennt 80 Literaturangaben.
Abstract (Originalsprache)
Vascular endothelial growth factor receptor 2 (VEGFR‐2) is a major mediator of pathological angiogenesis, which is critical to tumor progression and metastasis; therefore, inhibition of VEGFR‐2 remains a key therapeutic strategy for cancer. Despite the established clinical efficacy of several approved VEGFR‐2‐targeted agents, many first‐generation inhibitors are limited by dose‐limiting toxicities and the emergence of resistance, highlighting an ongoing need for next‐generation compounds with improved selectivity and more favorable safety profiles. Among nitrogen‐containing heterocyclic frameworks, triazoles and imidazoles are widely employed in medicinal chemistry owing to their favorable structural features, including appropriate stability, synthetic accessibility, and the ability to engage in key molecular interactions. This review summarizes recent advances in the design of triazole‐ and imidazole‐based VEGFR‐2 inhibitors, containing Schiff bases, bicyclic, tricyclic, and glycoside derivatives. We comparatively describe their VEGFR‐2 inhibitory activities and anticancer cytotoxicity data, and discuss key structure‐activity relationships and mechanistic insights, with particular emphasis on molecular features that appear to favor potent and selective VEGFR‐2 inhibition. This review compiles in vitro, in vivo, and in silico data on triazole‐ and imidazole‐based VEGFR‐2 inhibitors, providing a basis for understanding trends relevant to the design and development of optimized anti‐angiogenic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Universal Scientific Education and Research Network (USERN), Tehran, Iran.
- Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Parisa Nikfar, Mina Saeedi
Zitieren
APA
Nikfar, P., Hosseini, M., Rezaei, N., & Saeedi, M. (2026). Triazole‐ and Imidazole‐Containing Compounds: Versatile VEGFR‐2 Inhibitors for Cancer Therapy. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70330
Vancouver
Nikfar P, Hosseini M, Rezaei N, Saeedi M. Triazole‐ and Imidazole‐Containing Compounds: Versatile VEGFR‐2 Inhibitors for Cancer Therapy. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70330
BibTeX
@article{Nikfar2026,
author = {Nikfar, Parisa and Hosseini, Mina and Rezaei, Nima and Saeedi, Mina},
title = {Triazole‐ and Imidazole‐Containing Compounds: Versatile VEGFR‐2 Inhibitors for Cancer Therapy},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70330}
}
EUVIMED